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ABSTRACT: The hydrocarbon-stapled peptide E1S allosterically inhibits the
kinase activity of the epidermal growth factor receptor (EGFR) by blocking a
distant but essential protein−protein interaction: a coiled coil formed from the
juxtamembrane segment (JM) of each member of the dimeric partnership.1
Macrocyclization is not required for activity: the analogous unstapled (but
alkene-bearing) peptide is equipotent in cell viability, immunoblot, and
bipartite display experiments to detect coiled coil formation on the cell surface.
Recently we reported1 a group of hydrocarbon-stapledpeptides2 that allosterically inhibit the kinase activity of
the epidermal growth factor receptor3 (EGFR). The molecules
we described block a protein−protein interaction distal to the
kinase domain that is nonetheless essential for kinase
function.4,5 Specifically, these molecules block assembly of an
antiparallel coiled coil containing the juxtamembrane (JM)
segment from each member of the dimeric receptor partnership
(Figure 1A).1 Formation of the antiparallel JM coiled coil is
conformationally coupled to assembly of the catalytically active
asymmetric kinase dimer.4,6 The most potent molecule we
described, E1S, contains the sequence from the EGFR JM-A
region (residues 650 to 666),1 constrained by an i to i + 7
macrocyclic cross-link between residues 5 and 12 (654 and 661
according to EGFR numbering) (Figure 2A). In E1S, the cross-
link lies at position “c” of the heptad repeat, on the helix face
opposite the “a” and “d” positions used for coiled coil
formation within intact EGFR dimers.4 E1S decreases the
viability of EGFR-dependent cell lines, inhibits EGFR
autophosphorylation, and blocks coiled coil formation in live
cells.1 Here we report that macrocyclization per se is not
required for any of these metrics: the analogous unstapled (but
alkene-bearing) peptides are equipotent in cell viability,
immunoblot, and bipartite tetracysteine display6,7 experiments
that monitor coiled coil formation within the JM on the
mammalian cell surface.
In our previous work we noticed that the inhibitory potency
of a JM-derived stapled peptide in cell-based proliferation
assays was highly dependent on the location and identity of the
macrocyclic cross-link. Although at least three molecules
prepared previously (E1S, E2S, T4S) contained a cross-link
that should permit formation of a coiled coil dimer with a single
EGFR JM segment, only one (E1S) was highly active.1 We
prepared a series of E1S variants to investigate this structure−
actvity relationship further (Figure 2A and Figure S1−2). One
variant (JMAib) contained a pair of α-helix-promoting8 α-amino-
isobutyric acid (Aib) residues at positions 5 and 12, replacing
the alkene-bearing residues required for macro cyclization of
E1S. JMAib thereby decouples the functional contribution of α-
carbon quarternization and macrocyclization. A second,
“unstapled” variant (E1U) contained the alkene-bearing residues
required for macrocyclization of E1S, but no macrocyclization
reaction was performed. Analogous “unstapled” versions of the
remaining stapled peptides reported previously1 (E2U, E4U,
T1U, and T4U) were also prepared (Figure 1B), as were three
new, stapled peptides (E2.2S, T4.2S, and E2.3S, Figure 1C)
designed to further probe the role of staple placement on
EGFR inhibition. Two new molecules, E2.2S and T4.2S, contain
a single i to i + 3 cross-link that is displaced by one helix turn
from its position in E2S and T4S, respectively; the last, E2.3S,
contains an i to i + 7 cross-link (like E1S) between residues
located at two f positions of the heptad repeat.
As expected,9 when examined using circular dichrosim (CD)
spectroscopy all unstapled peptides displayed more α-helix
content than JMWT or JMAib but less than the analogous stapled
molecules. The ellipticity values at 222 nm (ε222) of E1
U, E2U,
E4U, T1U, and T4U all fall between −9000 and −15 700 deg·
cm2·dmol−1 with E4U at the low (less structured) end and E2U
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and E4U at the high (more structured) end (Figures 2B and
S3). The values reported for the analogous stapled molecules
range from −15 600 to −20 700 deg·cm2·dmol−1.1 Like the
stapled variants, the ε222 values of the unstapled peptides
increased little if at all in the 25 and 100 μM concentration
range (Figure S3), suggesting that all are predominantly
monomeric at the lower concentrations employed (1 to 10
μM).
Next we made use of five cell lines to evaluate the extent to
which each E1S variant modulated the viability of EGFR-
dependent cells. Four of the five cell lines express EGFR but
differ in the EGFR mutational state; one line does not express
EGFR (Figure 3). A431 and H2030 cells express wild type
EGFR, whereas H3255 and H1975 cells express single (L858R)
or double (L858R/T790M) mutant forms, respectively; SK-N-
MC cells express ErbB2−4 but not EGFR.10
The dose response curves in Figures 3 and S4 reveal several
trends. First, as expected, cells expressing WT EGFR (A431)
are sensitive to the small molecule tyrosine kinase inhibitor
Gefitinib11 and to the stapled peptides E1S and (less so) E2S,
but not the stapled peptides E4S, T1S, and T4S, even at
concentrations as high as 100 μM.1 Notably, the dose−
response curves for the unstapled versions of E1S and E2S (E1U
and E2U, respectively) are superimposable on those for the
analogous stapled molecule. In fact, even the dose−response
curves for the (virtually) inactive, stapled molecules (E4S and
T4S) are superimposable on the analogous unstapled variants
(E4U and T4U). The similarity in activity between stapled and
unstapled analogs is especially surprising since the former are
expected to possess longer half-lives in cellulo than the
latter.12,13 It is notable that the only sequence whose stapled
and unstapled analogs behave differently is T1, where the staple
replaces the leucine-rich interface required for formation of the
proposed peptide·JM coiled coil.
The similarity between the effects of stapled and unstapled
analogs are also apparent in H2030 and H1975 cells (Figure
3B,C) and the EGFR-deficient SK-N-MC cell line (Figure
S4A): E1S and E1U are equipotent, as are E2S and E2U. The
Figure 1. (A) Scheme illustrating the proposed interaction of the
hydrocarbon-stapled peptide2 E1S with the EGFR juxtamembrane
(JM) segment to inhibit coiled coil formation between two receptor
monomers and thus kinase activity.1 Helical wheel representation of
(B) unstapled alkene precursors to previously reported hydrocarbon-
stapled peptides E1S, E2S, E4S, T1S, and T4S and (C) three new,
stapled variants of E1S.
Figure 2. (A) Sequences and (B) circular dichrosim (CD) spectra of
of stapled and unstapled peptides studied herein. CD spectra of the
indicated peptides at 25 μM concentration in Dulbecco’s phosphate
buffered saline (dPBS); CD spectra of E1U at 25, 50, and 100 μM. See
also Figure S3.
Figure 3. Effect of stapled and unstapled peptides on the viability of
four EGFR-dependent cell lines. Each plot illustrates the % of viable
cells remaining after 18 h of treatment with the [ligand] shown.
Viability was assessed by monitoring oxyluciferin production by Ultra-
Glo luciferase. Error bars show standard error of the mean. Data
obtained using SK-N-MC cells, which do not express EGFR, are
shown in Figure S4A. Data for E2.2S, E2.3S, and E4.2S are shown in
Figure S4B−D.
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only instance where a stapled peptide and its unstapled analog
perform differently occurs in H3255 cells that express L858R
EGFR, a constitutively active EGFR mutant that is sensitive to
gefitinib and erlotinib. H3255 cells are 2-fold more sensitive to
E1S than to E1U, perhaps because of mutation-induced
differences in JM structure in these receptor variants. Although
previous reports might predict that the unstapled analog of an
active, stapled inhibitor would show diminished activity,13,14 we
find that E1S and E1U have nearly identical effects on the
viability of these five cell lines.
We also evaluated the activity of three, new, stapled peptide
variants of E1S and E2S. These molecules (E2.3S, E2.2S, and
T4.2S) were chosen to provide additional information about the
contribution of staple placement to inhibitor potency (Figure
S4B−D). E2.3S, which like E1S carries an i to i + 7 cross-link on
the helix face opposite that required for coiled coil formation, is
inactive in all cell lines examined, whereas E2.2S and T4.2S are
active at only the highest concentrations examined (IC50 > 100
μM) and equally active in SK-N-MC cells that do not express
EGFR (Figure S4A). Taken as a whole, the lack of activity
displayed by E2.3S, E2.2S, and T4.2S indicates that position “c”
of the heptad repeat is privileged with respect to inhibiting
EGFR in these cell lines. This observation may reflect the
requirement for multiple α-helix faces or binding modes;
further work on this front is in progress.
In our previous work, we performed immunoblotting
experiments to monitor the effect of each stapled peptide on
the phosphorylation of EGFR and the downstream factors Akt
and Erk in A431 cells.1 The stapled peptide E1S caused a dose-
dependent decrease in EGFR autophosphorylation at several
positions within the C-terminal tail. E1S inhibited phosphor-
ylation at Y845, Y1045, Y1086, and Y1173, but not Y1068 and
Y1148. A431 cells treated with E1S also showed decreased
levels of phospho-Akt and phospho-Erk, whereas the levels of
EGFR, Akt, and Erk themselves were unaffected.1
Treatment of A431 cells with an equivalent concentration of
E1U led to a pattern of phosphorylation changes within EGFR,
Akt, and Erk that was virtually identical to that seen with E1S
(Figure 4). The only detectable difference between the effects
of E1S and E1U is the relative decrease in phosphorylation of
Y1173. In cells treated with E1S, the level of phosphorylated
Y1173 is downregulated more than in cells treated with E1U.
Thus, in A431 cells, the effects of E1S and E1U on EGFR
signaling are virtually identical; the small difference in α-helicity
observed in vitro (Figure 2) has no significant effect on EGFR
inhibitory potency. E1S, E1U, T1S, T1U, E2.2S, and E4.2S all
reached the cytosol of H2030 cells with comparable efficiencies
when evaluated using the recently reported GIGT assay15
(Figure S6), suggesting that, in these cases, the presence of a
lipophilic side chain contributes more to permeability than does
macrocylization per se.
The experiments described above suggest that E1U, like E1S,
allosterically inhibits the kinase activity of EGFR, presumably
through an interaction with the distal juxtamembrane segment
(Figure 1). To evaluate whether the mode of inhibition by E1U
also mimics that of E1S,1 we made use of a validated bipartite
tetracysteine display assay6,7,16 to determine whether E1U
would also inhibit JM coiled coil formation within full length
EGFR dimers expressed on the cell surface. CHO-K1 cells that
transiently expressed the CysCys EGFR variant CCH-1 (whose
cysteine arrangement in the paired EGF-induced dimer
supports ReAsH binding and fluorescence)6 were exposed
individually to E1S and E1U as well as JMAib, stimulated with
EGF, and incubated with ReAsH, and the fluorescence increase
due to ReAsH was quantified using total internal reflectance
fluorescence microscopy (TIRF-M) (Figure 5). Treatment with
EGF alone led to the expected increase in ReAsH fluorescence
at the cell surface; this increase was unchanged by the presence
of JMAib. However, treatment of cells with 1 μM E1S or E1U led
to a significant loss in ReAsH fluorescence. Neither E1S nor
E1U affected ReAsH fluorescence in the absence of EGF
(Figure 5). We conclude that E1U, like E1S, inhibits the
intradimer coiled coil required for assembly of the active
asymmetric kinase dimer. Like E1S, E1U is an allosteric inhibitor
of EGFR. Experiments to identify the precise binding site(s) of
E1S and E1U are in progress and will be reported in due course.
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Figure 4. Comparison of the effects of E1S and E1U on EGFR
autophosphorylation and on phosphorylation of Akt and Erk1/2. A431
cells were treated with 10 μM of either E1S or E1U 2 for 1 h, stimulated
with 10 ng/mL EGF, and then lysed, immunoblotted, and visualized.
Plots show the decrease in intensity of the indicated phospho-protein
band relative to untreated cells. Error bars represent the standard error
of the mean over at least four trials. Immunoblots of A431 cells treated
with E2.2S, T4.2S, and E2.3S are found in Figure S5.
Figure 5. Comparison of the effects of E1S and E1U on formation of
the EGF-induced coiled coil within the EGFR JM using TIRF-M and
bipartite tetracysteine display. CHO-K1 cells were transfected with
plasmid encoding EGFR CCH-1,
6 treated with 1 μM of the indicated
ligand for 1 h, stimulated in the presence or absence of 100 ng/mL
EGF for 30 min, and labeled with ReAsH. The plot illustrates the
change in ReAsH fluorescence at 568 nm of n CHO-K1 cells relative
to the level of EGFR expression. Error bars represent the standard
error of the mean: **p < 0.01, ****p < 0.0001; one-way ANOVA with
Bonferroni postanalysis accounting for multiple comparisons.
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